Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DEGLYCAR-T

Financiado

Cerrado

Engineering CAR-T cells to overcome glycosylation-driven tumour resistance

T cells engineered to express tumour-specific chimeric antigen receptors (CAR) proved effective against B-cell tumours. However, as the technology moves to solid cancers, clinical responses have not been as robust. In this setting... ver más

31/03/2028

OSR

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-06

ERC-2022-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OSR

1.50M€ | Lider

Proyectos interesantes

PID2020-117552RB-I00

Medical Technol...

Biotechnology

277K€ Cerrado

PID2019-108989RB-I00

Medical Technol...

Biotechnology

157K€ Cerrado

GlycoTherapy

Medical Technol...

Data Science

2M€ Cerrado

PID2021-128283OA-I00

Medical Technol...

Biotechnology

157K€ Cerrado

PID2019-108357RB-I00

Medical Technol...

Immunology

230K€ Cerrado

TARG-SUP

Medical Technol...

Immunology

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2023-03-06
Fecha Fin: 2028-03-31

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto T cells engineered to express tumour-specific chimeric antigen receptors (CAR) proved effective against B-cell tumours. However, as the technology moves to solid cancers, clinical responses have not been as robust. In this setting, several barriers need to be overcome, including poor tumour recognition and a highly immunosuppressive tumour microenvironment (TME). Altered glycosylation is a hallmark of cancer, often manifesting as incomplete synthesis of O-glycans and increased branching of N-glycans. Glycosylation can mask epitopes to antibodies recognition and suppress anticancer immunity. My Unit was the first to report that N-glycans protect tumours from CAR-T cells and that pharmacological inhibition of N-glycosylation improves efficacy of CAR-T cell therapy in solid malignancies. With the aim of generating a single cell product able to safely offset multiple barriers of tumour resistance, I propose to engineer CAR-T cells to locally express an enzyme able to de-glycosylate tumour and TME cells. This goal will be achieved through the selection of a mutant able to deglycosylate the surface proteome of target cells. To regulate its function in CAR-T cells, I plan to test different systems based on the use of specific promoters, the inclusion of artificial miRNA target sequences, or the generation of a transmembrane variant. A deep characterization of the selected product will be performed in mice reconstituted with a human haemopoietic system. This model will allow to study the efficacy and safety of the proposed approach, and to assess its ability to remodel the TME toward a pro-inflammatory state. I believe that this project will have an immediate impact on cancer immunotherapy, will fuel the development of antiviral approaches and will provide new technological platforms. I have a deep knowledge of CAR-T cell therapy and have established a great network in the field. Despite ambitious, I believe I have the right skills and tools to make this project a reality.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores